Ondansetron Accord

Ondansetron, the active ingredient in Ondansetron Accord, is a 5-HT3 receptor antagonist presented as a 4 mg oral tablet for systemic use. It helps prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult patients.

GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Accord is a selective 5‑HT3 receptor antagonist used across several emesis‑related pathways. - Chemotherapy‑induced nausea and vomiting (CINV): reduces the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting (RINV): helps control nausea during and after radiation treatment. - Post‑operative nausea and vomiting (PONV): lowers the incidence of nausea and vomiting after surgical procedures.

Side effects reported with ondansetron are generally mild to moderate and vary by individual.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Diarrhoea: loose stools in a minority of patients. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: transient light‑headed sensations.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with high intravenous doses. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests in isolated cases.

When prescribing Ondansetron Accord, clinicians should consider several safety aspects. - Cardiac monitoring: assess baseline ECG in patients with known cardiac disease or electrolyte imbalance. - Electrolyte balance: correct hypokalaemia or hypomagnesaemia before use. - Drug interactions: review concomitant medications that may affect QT interval. - Pregnancy: use only if the potential benefit outweighs risk; data are limited. - Breastfeeding: limited data, weigh benefits against possible infant exposure. - Store at below 25°C: keep in the original container, protect from moisture and light.

Ondansetron may interact with several medicines that influence cardiac rhythm or serotonergic pathways.

Major Interactions (Avoid): - Class I anti‑arrhythmic agents (e.g., quinidine, procainamide): increase risk of QT prolongation. - Certain antifungal agents (e.g., ketoconazole, itraconazole): potentiate QT prolongation. - Serotonergic drugs (e.g., tramadol, linezolid, SSRIs): raise the risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., erythromycin, azithromycin): may modestly extend QT interval. - Certain antipsychotics (e.g., haloperidol, ziprasidone): additive effect on cardiac repolarisation. - Calcium channel blockers (e.g., amlodipine, verapamil): can affect ondansetron metabolism.